20-HA mRNA(20-HA mRNA) - 药物靶点：hemagglutinin_在研适应症：甲型流感病毒感染，乙型流感病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、mRNA疫苗

别名

a nucleoside-modified mRNA-lipid nanoparticle vaccine、a nucleoside-modified mRNA–lipid nanoparticle vaccine

靶点

hemagglutinin

作用机制

hemagglutinin抑制剂(血凝素抑制剂)

治疗领域

感染呼吸系统疾病

在研适应症

甲型流感病毒感染乙型流感病毒感染

非在研适应症-

原研机构

University of Pennsylvania

Acuitas Therapeutics, Inc.

在研机构

University of Pennsylvania

Acuitas Therapeutics, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 20-HA mRNA 相关的临床结果

登录后查看更多信息

100 项与 20-HA mRNA 相关的转化医学

登录后查看更多信息

100 项与 20-HA mRNA 相关的专利（医药）

登录后查看更多信息

4

项与 20-HA mRNA 相关的文献（医药）

2024-06-26·Cureus

Retraction

作者: Kojima, Seiji ; Fujisawa, Akinori ; Kikuchi, Takayuki ; Fukushima, Masanori ; Gibo, Miki

[This retracts the article DOI: 10.7759/cureus.57860.].

2024-06-12·Cureus

Expression of Concern

作者: Kojima, Seiji ; Fujisawa, Akinori ; Kikuchi, Takayuki ; Gibo, Miki ; Fukushima, Masanori

2024-04-08·Cureus

Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan

Article

作者: Fujisawa, Akinori ; Kojima, Seiji ; Kikuchi, Takayuki ; Fukushima, Masanori ; Gibo, Miki

During the COVID-19 pandemic, excess deaths including cancer have become a concern in Japan, which has a rapidly aging population. Thus, this study aimed to evaluate how age-adjusted mortality rates (AMRs) for different types of cancer in Japan changed during the COVID-19 pandemic (2020-2022). Official statistics from Japan were used to compare observed annual and monthly AMRs with predicted rates based on pre-pandemic (2010-2019) figures using logistic regression analysis. No significant excess mortality was observed during the first year of the pandemic (2020). However, some excess cancer mortalities were observed in 2021 after mass vaccination with the first and second vaccine doses, and significant excess mortalities were observed for all cancers and some specific types of cancer (including ovarian cancer, leukemia, prostate cancer, lip/oral/pharyngeal cancer, pancreatic cancer, and breast cancer) after mass vaccination with the third dose in 2022. AMRs for the four cancers with the most deaths (lung, colorectal, stomach, and liver) showed a decreasing trend until the first year of the pandemic in 2020, but the rate of decrease slowed in 2021 and 2022. This study discusses possible explanations for these increases in age-adjusted cancer mortality rates.

100 项与 20-HA mRNA 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲型流感病毒感染	临床前	全球	Acuitas Therapeutics, Inc.	2022-11-25
甲型流感病毒感染	临床前	全球	University of Pennsylvania	2022-11-25
乙型流感病毒感染	临床前	全球	University of Pennsylvania	2022-11-25
乙型流感病毒感染	临床前	全球	Acuitas Therapeutics, Inc.	2022-11-25